MX2009001966A - Metodo de reduccion del daño celular neuronal. - Google Patents

Metodo de reduccion del daño celular neuronal.

Info

Publication number
MX2009001966A
MX2009001966A MX2009001966A MX2009001966A MX2009001966A MX 2009001966 A MX2009001966 A MX 2009001966A MX 2009001966 A MX2009001966 A MX 2009001966A MX 2009001966 A MX2009001966 A MX 2009001966A MX 2009001966 A MX2009001966 A MX 2009001966A
Authority
MX
Mexico
Prior art keywords
neuronal cell
cell damage
subject
combination
pharmaceutical agent
Prior art date
Application number
MX2009001966A
Other languages
English (en)
Inventor
David J Poulsen
Thomas Frederick Rau
Original Assignee
Univ Montana
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montana filed Critical Univ Montana
Publication of MX2009001966A publication Critical patent/MX2009001966A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se dirige a un método de reducción de la ocurrencia de daño celular neuronal, inclusive la muerte, causada por la hipoxia y/o isquemia cerebral transiente. El método comprende las etapas de: diagnosticar a un sujeto que tiene una condición hipóxica y/o isquémica cerebral transiente; y dentro de 16 horas después del inicio de la condición, administrar al sujeto una cantidad neuroprotectora de un agente farmacéutico. El agente farmacéutico de preferencia se selecciona del grupo que consiste de: un estimulante del sistema nervioso central (CNSS), neurotransmisor de monoamina, inhibidor de monoamina oxidasa (MAOI), antidepresivo tricíclico (TCA), o una combinación de los mismos. Los agentes preferidos incluyen anfetaminas, metanfetamina, metilfenidato, metilen-dioximetenafetamina, o una combinación de los mismos.
MX2009001966A 2006-08-23 2007-08-15 Metodo de reduccion del daño celular neuronal. MX2009001966A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83997406P 2006-08-23 2006-08-23
PCT/US2007/076034 WO2008024660A2 (en) 2006-08-23 2007-08-15 Method of reducing neuronal cell damage

Publications (1)

Publication Number Publication Date
MX2009001966A true MX2009001966A (es) 2009-06-19

Family

ID=39107537

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009001966A MX2009001966A (es) 2006-08-23 2007-08-15 Metodo de reduccion del daño celular neuronal.

Country Status (14)

Country Link
US (1) US20100249242A1 (es)
EP (1) EP2053919B1 (es)
JP (1) JP5243428B2 (es)
KR (1) KR101494675B1 (es)
CN (2) CN101516194B (es)
AU (1) AU2007286933B2 (es)
BR (1) BRPI0715633A2 (es)
CA (1) CA2661495C (es)
ES (1) ES2452341T3 (es)
IL (1) IL197194A (es)
MX (1) MX2009001966A (es)
RU (1) RU2464977C2 (es)
WO (1) WO2008024660A2 (es)
ZA (1) ZA200901318B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105621A1 (en) * 2006-08-23 2011-05-05 The University Of Montana Method of reducing brain cell damage, inflammation or death
CN105530924A (zh) 2013-09-06 2016-04-27 蒙大拿大学 用卤代烷基胺减少神经元细胞死亡的方法
KR20150080706A (ko) * 2014-01-02 2015-07-10 서울대학교산학협력단 N-말단 법칙 경로의 저해용 조성물 및 방법
WO2018107132A1 (en) * 2016-12-11 2018-06-14 Kempharm, Inc. Compositions comprising methylphenidate-prodrugs, processes of making and using the same
WO2018107131A1 (en) * 2016-12-11 2018-06-14 Kempharm, Inc. Methylphenidate-prodrugs, processes of making and using the same
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP6753434B2 (ja) 2018-06-13 2020-09-09 ダイキン工業株式会社 ジフルオロエチレンの製造方法
RU2696203C1 (ru) * 2018-09-10 2019-07-31 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики церебральной ишемии
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010145A1 (en) * 1991-11-12 1993-05-27 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
SE520730C2 (sv) * 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6315995B1 (en) * 1996-09-27 2001-11-13 The Trustees Of Columbia University In The City Of New York Methods for treating an ischemic disorder and improving stroke outcome
WO1999064028A1 (en) * 1998-06-11 1999-12-16 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Protecting neurons from ischemia
US20050059743A1 (en) * 2000-11-01 2005-03-17 Sention, Inc. Methods for treating mild cognitive impairment and alzheimer's disease
US20030119884A1 (en) * 2000-11-01 2003-06-26 Epstein Mel H. Methods and compositions for regulating memory consolidation
AU2002239464B2 (en) * 2000-11-01 2007-01-04 Cognition Pharmaceuticals Llc Methods and compositions for regulating memory consolidation
US20030232890A1 (en) * 2000-11-01 2003-12-18 Sention, Inc. Methods for treating an impairment in memory consolidation
US20070117869A1 (en) * 2000-11-01 2007-05-24 Cognition Pharmaceuticals Llc Methods for treating coginitive impairment and improving cognition
US7619005B2 (en) * 2000-11-01 2009-11-17 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans with Multiple Sclerosis
US20070099999A1 (en) * 2000-11-01 2007-05-03 Epstein Mel H Methods of treating depression
WO2005000203A2 (en) * 2001-10-31 2005-01-06 Sention, Inc. Methods for treating cognitive impairment and improving cognition
US20100022658A1 (en) * 2000-11-01 2010-01-28 Cognition Pharmaceuticals Llc Methods for treating cognitive impairment in humans
US7700561B2 (en) * 2002-02-22 2010-04-20 Shire Llc Abuse-resistant amphetamine prodrugs
WO2004039403A1 (ja) * 2002-10-31 2004-05-13 Senju Pharmaceutical Co., Ltd. 角膜障害治療剤
RU2251429C2 (ru) * 2002-12-30 2005-05-10 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Фармацевтическая композиция для лечения ишемического инсульта и способ лечения
US20040176378A1 (en) * 2003-02-12 2004-09-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an amphetamine for the treatment of reduced blood flow to the central nervous system
WO2004103283A2 (en) * 2003-05-14 2004-12-02 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage

Also Published As

Publication number Publication date
ES2452341T3 (es) 2014-04-01
IL197194A (en) 2015-06-30
EP2053919B1 (en) 2013-12-25
WO2008024660A2 (en) 2008-02-28
RU2464977C2 (ru) 2012-10-27
US20100249242A1 (en) 2010-09-30
AU2007286933B2 (en) 2013-04-04
JP5243428B2 (ja) 2013-07-24
KR101494675B1 (ko) 2015-02-23
CN103479603A (zh) 2014-01-01
JP2010501581A (ja) 2010-01-21
RU2009110273A (ru) 2010-09-27
IL197194A0 (en) 2009-12-24
CN103479603B (zh) 2016-06-22
EP2053919A4 (en) 2012-12-26
CN101516194B (zh) 2015-01-21
EP2053919A2 (en) 2009-05-06
CN101516194A (zh) 2009-08-26
AU2007286933A1 (en) 2008-02-28
WO2008024660A3 (en) 2008-11-20
ZA200901318B (en) 2012-07-25
CA2661495C (en) 2017-05-02
HK1131003A1 (en) 2010-01-15
KR20090059125A (ko) 2009-06-10
BRPI0715633A2 (pt) 2013-07-02
CA2661495A1 (en) 2008-02-28

Similar Documents

Publication Publication Date Title
WO2008024660A3 (en) Method of reducing neuronal cell damage
BRPI0510305A (pt) composto ou um sal do mesmo, pródroga ou um sal da mesma, agente farmacêutico, método de produção do composto ou um sal do mesmo, inibidor de metaloproteinase de matriz ou um sal do mesmo ou uma pródroga do mesmo, método de inibir uma metaloproteinase de matriz, e, uso de um composto ou de um sal do mesmo ou de uma pródroga do mesmo
TW200619199A (en) 3-carbamoyl-2-pyridone derivatives
ECSP078003A (es) Inhibidores de aspartil proteasas
BRPI0415960A (pt) composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, uso de um composto,e, método para produzir um composto
EP2067467A3 (en) Compositions and methods for treating keratinous substrates
WO2004047838A3 (de) Pharmazeutische zusammensetzung aus beta-3-adrenozeptor-agonisten und antimuskarinika
MA30821B1 (fr) Derives de pyrazoline utiles comme antagonistes des recepteurs de mineralocorticoïdes
EP1698335A4 (en) AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR
WO2006012642A3 (en) Pyrrole derivatives as pharmaceutical agents
WO2009118765A8 (en) Novel monoamine re-uptake inhibitor
ATE277039T1 (de) Farnesyltransferase-inhibitoren die eine pyrrolstruktur haben und verfahren zu ihrer herstellung
WO2010019450A3 (en) Synergizing active compounds for treating inflammation and other conditions
Panciera et al. Discovery of 3H-pyrrolo [2, 3-c] quinolines with activity against Mycobacterium tuberculosis by allosteric inhibition of the glutamate-5-kinase enzyme
EP1262196A3 (en) Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
CO6260011A2 (es) Uso de (4-metoxi-7-morfolin-4-il-benzotiazol-2-il)-amida del acido 4-hidroxi-4-metil-piperidin-1- carboxilico para el tratamiento del trastorno por estres postraumatico
TW200508195A (en) 3-aminopyrrolidines as inhibitors of monoamine uptake
Ling et al. Synthesis of N-propargylphenelzine and analogues as neuroprotective agents
DalBó et al. Analysis of the antinociceptive effect of the proanthocyanidin-rich fraction obtained from Croton celtidifolius barks: evidence for a role of the dopaminergic system
Palea et al. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum
MX2007006081A (es) Tetrahidroisoquinolinas 4-fenil-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina.
UY29212A1 (es) Azabenzoxazoles para el tratamiento de trastornos del snc
Sawynok et al. Peripheral interactions between dextromethorphan, ketamine and amitriptyline on formalin-evoked behaviors and paw edema in rats
Ono et al. Protective effect of R (-)-1-(benzo [b] thiophen-5-yl)-2-[2-(N, N-diethylamino) ethoxy] ethanol hydrochloride (T-588), a novel cerebral activator, against experimental cerebral anoxia
GEP20094682B (en) Tricyclic pyrazole derivatives as cannabinoid receptor modulators

Legal Events

Date Code Title Description
FG Grant or registration